Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide

Shingo Eikawa, Kazuhiro Kakimi, Midori Isobe, Kiyotaka Kuzushima, Immanuel Luescher, Yoshihiro Ohue, Kazuhiro Ikeuchi, Akiko Uenaka, Hiroyoshi Nishikawa, Heiichiro Udono, Mikio Oka, Eiichi Nakayama

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Immunogenicity of a long 20-mer NY-ESO-1f peptide vaccine was evaluated in a lung cancer patient TK-f01, immunized with the peptide with Picibanil OK-432 and Montanide ISA-51. We showed that internalization of the peptide was necessary to present CD8 T-cell epitopes on APC, contrasting with the direct presentation of the short epitope. CD8 T-cell responses restricted to all five HLA class I alleles were induced in the patient after the peptide vaccination. Clonal analysis showed that B*35:01 and B*52:01-restricted CD8 T-cell responses were the two dominant responses. The minimal epitopes recognized by A*24:02, B*35:01, B*52:01 and C*12:02-restricted CD8 T-cell clones were defined and peptide/HLA tetramers were produced. NY-ESO-1 91-101 on A*24:02, NY-ESO-1 92-102 on B*35:01, NY-ESO-1 96-104 on B*52:01 and NY-ESO-1 96-104 on C*12:02 were new epitopes first defined in this study. Identification of the A*24:02 epitope is highly relevant for studying the Japanese population because of its high expression frequency (60%). High affinity CD8 T-cells recognizing tumor cells naturally expressing the epitopes and matched HLA were induced at a significant level. The findings suggest the usefulness of a long 20-mer NY-ESO-1f peptide harboring multiple CD8 T-cell epitopes as an NY-ESO-1 vaccine. Characterization of CD8 T-cell responses in immunomonitoring using peptide/HLA tetramers revealed that multiple CD8 T-cell responses comprised the dominant response. What's new? An antigen called NY-ESO-1 is expressed by a wide range of human cancers, and has shown promise as a cancer vaccine. In this study, the authors studied a peptide derived from that antigen, and analyzed the cellular and molecular mechanisms that allow the peptide to provoke an immune response. They found that the peptide must be internalized by antigen-presenting cells (APCs) in order to yield T-cells that can attack tumours via the NY-ESO-1 antigen. These data increase our understanding of the requirements for an effective therapeutic cancer vaccine. (This section added after initial online publication.)

Original languageEnglish
Pages (from-to)345-354
Number of pages10
JournalInternational Journal of Cancer
Issue number2
Publication statusPublished - Jan 15 2013


  • CD8 T-cell response
  • NY-ESO-1
  • cancer vaccine
  • long peptide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide'. Together they form a unique fingerprint.

Cite this